GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » FCF Yield %

Novavax (Novavax) FCF Yield % : -131.31 (As of Apr. 29, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Novavax FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Novavax's Trailing 12-Month Free Cash Flow is $-772.8 Mil, and Market Cap is $588.5 Mil. Therefore, Novavax's FCF Yield % for today is -131.31%.

The historical rank and industry rank for Novavax's FCF Yield % or its related term are showing as below:

NVAX' s FCF Yield % Range Over the Past 10 Years
Min: -175.25   Med: -14.01   Max: 5.98
Current: -131.31


During the past 13 years, the highest FCF Yield % of Novavax was 5.98%. The lowest was -175.25%. And the median was -14.01%.

NVAX's FCF Yield % is ranked worse than
87.67% of 1549 companies
in the Biotechnology industry
Industry Median: -15.5 vs NVAX: -131.31

Novavax's FCF Margin % for the quarter that ended in Dec. 2023 was -73.35%.


Novavax FCF Yield % Historical Data

The historical data trend for Novavax's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax FCF Yield % Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -107.55 -1.23 2.45 -57.54 -115.40

Novavax Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.26 -233.55 -102.59 -27.01 -111.02

Competitive Comparison of Novavax's FCF Yield %

For the Biotechnology subindustry, Novavax's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Novavax's FCF Yield % falls into.



Novavax FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Novavax's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-772.773 / 669.6288
=-115.40%

Novavax's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-185.859 * 4 / 669.6288
=-111.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novavax FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Novavax FCF Yield % Related Terms

Thank you for viewing the detailed overview of Novavax's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (Novavax) Business Description

Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100